Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

LXEO Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$546K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$546K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$546K or moves back toward the trailing-twelve-month quarterly average of -$136.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$546K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$546K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How LXEO compares with its peers on the latest reported figures

  • LXEO's LTM Mar 2026 gross profit of -$546K is the 7th highest of the 11 companies compared; the peer median is -$303.82K.
LXEO Competitors Peer median
Gross Profit for LXEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$201.36M +7.0%-4.1%92.5%
AMRNAmarin Corporation plcLTM Mar 2026$112.77M +52.6%-20.7%52.5%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K —-62.8%66.4%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$79K ———
MREOMereo BioPharma Group plcLTM Mar 2026-$528.63K +51.3%+12.5%105.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$546K ———
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$866K +97.1%——
DBVTDBV Technologies S.A.LTM Mar 2026-$17.4M -146.9%——
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$31.63M +46.9%—86.7%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$42.41M -4.9%——
Peer median (excluding LXEO) -$303.82K+46.9%-12.4%86.7%

Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.66M654K000
Cost of Revenue00000
Gross Profit1.66M654K000
Gross Margin100.0%100.0%———
Research & Development45.12M49.16M53.13M74.09M63.8M
Selling, General & Admin7.17M12M15.38M31.68M45.46M
Operating Expenses52.29M61.16M68.51M105.77M109.26M
Depreciation & Amortization13K1.15M1.84M2M2.08M
EBITDA(50.61M)(58.04M)(64.35M)(96.19M)(97.68M)
EBITDA Margin-3054.3%-8874.8%———
Operating Income(50.64M)(60.51M)(68.51M)(105.77M)(109.26M)
Operating Margin-3055.9%-9252.1%———
Interest Income15K1.33M2.87M7.56M6.13M
Interest Expense091K205K114K206K
Other Income / Expenses15K1.23M2.12M7.43M9.3M
Income Before Tax(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Pre-Tax Margin-3055.0%-9063.8%———
Income Tax Expense00000
Net Income(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Net Margin-3055.0%-9063.8%———
EPS (Basic)(2.01)(2.36)(2.49)(3.09)(1.86)
EPS (Diluted)(2.01)(2.40)(2.49)(3.09)(1.86)
Weighted Avg Shares25.17M25.17M26.65M31.79M53.65M
Weighted Avg Shares (Diluted)25.17M25.17M26.65M31.79M53.65M

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Intrinsic Alpha fair value

Locked

Current Price

$2.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.